{
    "id": "3f053e7a-0f0f-4e33-8288-15aaf51f6c56",
    "indications": "Relapsed or Refractory Acute Myeloid Leukemia\n                  \n                  REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test [see Dosage and Administration (2.1), Clinical Pharmacology (12.1), and Clinical Studies (14.1)].",
    "contraindications": "Select patients based on presence of IDH1 mutation(s). ( 2.1 ) Recommended dosage: 150 mg orally twice daily, until disease\nprogression or unacceptable toxicity. ( 2.2 ) Take on an empty stomach at least 1 hour before or 2 hours after a\nmeal. ( 2.2 )",
    "warningsAndPrecautions": "How Supplied\n                  \n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           Capsule Strength\n                           Description\n                           Package Configuration\n                           NDC Number\n                        \n                        \n                           150 mg\n                           White hard gelatin capsules with black ink print \"OLU 150\"\n                           White high-density polyethylene (HDPE) bottle with child-resistant closure\n                           71332-005-01\n                        \n                        \n                           \n                           \n                           Each bottle contains 30 capsules\n                           \n                        \n                     \n                  \n                  \n                     Storage\n                  \n                  Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F)[see USP Controlled Room Temperature].",
    "adverseReactions": "None.",
    "ingredients": [
        {
            "name": "OLUTASIDENIB",
            "code": "0T4IMT8S5Z"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        }
    ],
    "organization": "Rigel Pharmaceuticals, Inc.",
    "name": "REZLIDHIA",
    "effectiveTime": "20250430"
}